European Urology

Papers
(The H4-Index of European Urology is 65. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Re: Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer1172
Manfred Wirth – A life devoted to urology in a time of change1126
Editorial Board653
The Platinum Hall of Fame575
More Than Words: Defining Adjuvant, Consolidative, and Salvage Treatment after Radical Prostatectomy560
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial533
Honing Stratification and Treatment for High-risk Prostate Cancer401
Re: Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma391
Re: Carlotta Nedbal, Patrick Juliebø-Jones, Eamonn Rogers, et al. Improving Patient Information and Enhanced Consent in Urology: The Impact of Simulation and Multimedia Tools. A Systematic Literature 337
Editorial Board333
Prostate Cancer Active Surveillance Without Biopsy? Not Quite Yet, but Watch This Space253
Reply to Nour Khalil, Guiseppe Maiolino, and Eric Barret’s Letter to the Editor re: Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner. Intraductal Carcinoma and Cribriform Pattern in Prosta246
Do women choose urology residency as much as men? Female urology resident representation in Spain in the last decade230
Development and validation of a new personalized algorithmic model for PSA analysis : PROSTia202
Re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential189
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger’s Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinica182
Re: Local Anaesthetic Transperineal Biopsy Versus Transrectal Prostate Biopsy in Prostate Cancer Detection (TRANSLATE): A Multicentre, Randomised, Controlled Trial173
Re: Marcio Covas Moschovas, Shady Saikali, Marco Sandri, et al. Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robot169
Reply to Jonas Hugosson. Population-based Screening for Prostate Cancer: Is It Time? Eur Urol. 2025;87:340–341161
Re: W. Marston Linehan, Cathy Anne Pinto, Yanfang Liu, et al. Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease. Eur Urol 2025;88:56–63156
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder156
Acknowledgement to Reviewers142
Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Random135
Reply to Laurence Klotz’s Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of “Manels” in Major Urology126
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy126
Delayed absent ejaculation in men presenting to the fertility clinic – retrospective cohort study121
Congress Calendar120
SWL is more cost-effective than fURS for the management of kidney stones: Comparative study in a tertiary care centre117
The impact of adjuvant chemotherapy on overall survival in patients with node-positive Upper Tract Urothelial Carcinoma (UTUC): Improving precision in medicine with a risk-stratified approach114
Comparing urine and stone microbiome in urolithiasis patients113
Re: Association of Black Race with Prostate Cancer–specific and Other-cause Mortality105
Prostatic artery embolization compared to trans-urethral resection of the prostate and prostatic urethral lift: A real-world population-based study104
A randomized controlled trial comparing 1470nm diode laser vs. plasmakinetic enucleation of the prostate for treating benign prostatic hyperplasia104
Utility of robotic platform for upper and mid ureteric reconstruction: Our experience at MPUH, Nadiad102
The complications of synthetic mid-urethral slings: The discrepancy between demographic data and clinical trials- a systematic review with meta-analysis99
The use of abdominal drain after robot-assisted surgery in urology: Impact on postoperative pain99
Hsa_circ_0005221 promotes prostate cancer progression through miR-339-5p/ STAT5a98
Intravesical injection with abobotulinumtoxin-A in patients with bladder pain syndrome/ interstitial cystitis98
Gender disparities in editorial board of academic urology journals96
Efficacy of tamsulosin versus mirabegron for ureteric stent related symptoms: Prospective randomized questionnaire based comparison92
Spontaneous passage rate of ureteral stones and predictive factors after pre-stenting91
First clinical experience with a novel approach of robot-assisted completely retroperitoneal nephroureterectomy with bladder cuff89
Comparison of clinical outcomes after phalloplasty with versus without urethral lengthening in transgender men88
The surgical learning curve for cancer control after robot-assisted radical prostatectomy87
The feasibility and advantages of an at-home intravesical therapy service for benign conditions85
Management of renal cell carcinoma in transplant kidney: An individual patient data meta-analysis and evidence-based guide84
Evaluation of the effect of umbilical cord derived urethral slings in bilateral pudendal nerves injury-induced urinary incontinence in female rats82
Do patients prefer telecommunication to traditional face-to face clinic review: A benefit of covid-19?81
Outcomes according to histological variants of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial77
Efficacy of recombinant Bacillus Calmette-Guérin–dltA in three-dimensional bioprinted bladder cancer-on-a-chip with microfluidic system76
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution75
The effect of duration between sessions on biofeedback treatment in children with dysfunctional voiding75
The next generation trial: Assessing 18F-PSMA-1007 positron emission tomography and magnetic resonance imaging in the primary staging of prostate cancer patients74
Persistently elevated urinary inflammatory biomarkers may predict recurrence of recurrent urinary tract infection in women74
The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance74
Salvage focal ablation versus radical prostatectomy for localized radiorecurrent prostate cancer: A propensity-score matched comparison74
Impact of systemic therapy in clinical T1 small-cell neuroendocrine carcinoma of the bladder73
Validation of a simplified prognostic model for survival in patients with extrinsic malignant ureteral obstruction treated with tandem ureteral stents72
Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer72
Prospective randomized comparison of SP TFL and Ho:YAG in RIRS for kidney stones: a single-center study72
Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study70
Putting Precision Medicine in Prostate Cancer into Practice: Are We There Yet?69
Robot-assisted radical prostatectomy for prostate cancer: 18-year oncological outcomes from a Belgian high-volume center68
Which men with cN1 prostate cancer at PSMA PET/CT represent the ideal candidate for radical prostatectomy? Development of a novel risk stratification tool for individualized approaches based on a larg67
Transcriptomic analysis of the lncRNA-miRNA-mRNA axis network in aldosterone-producing adenoma65
0.091408967971802